The financials
Celldex Therapeutics, Inc. by the numbers
Celldex Therapeutics, Inc. (CLDX) reported revenue of $22K in Q2 2026 (quarter ended Jun 30, 2026), down 97% from the same quarter a year earlier. That came with net loss of $74M. For the full year FY2025, revenue was $1.5M (−78% year on year) and net income −$259M. Its largest product in Q2 2026 was Grant at $15K, 68% of the disclosed total, well ahead of Service at 32%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $22K | $730K | −97% |
| Operating income | −$81M | −$64M | n/a |
| Net income | −$74M | −$57M | n/a |
| Diluted EPS | −$0.94 | −$0.85 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Grant | $15K | 68% |
| Service | $7K | 32% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $22.0K (+47%)
Service grew 0.00% year on yearGrant -98% year on year
Segment Latestquarter on quarteryear on year
- Grant$15.0K$15.0KQoQ 0.00%year on year -98%0.00%-98%
- Service$7.0K$7.0KQoQ -year on year 0.00%-0.00%